Nature Reviews Clinical Oncology - Table of Contents alert Volume 11 Issue 3

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
March 2014 Volume 11 Number 3
Impact Factor 15.031 *	In this issue Research Highlights News and Views Reviews Also this month  Featured article: Molecular analysis of circulating tumour cells—biology and biomarkers Matthew G. Krebs, Robert L. Metcalf, Louise Carter, Ged Brady, Fiona H. Blackhall & Caroline Dive
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
nature.com webcasts Macmillan Science Communication presents a custom webcast: Biomarkers and immunoassays: Enhancing your research with multiplex cytokine profiling. Thursday 20 March at 8am PDT / 11am EDT / 3pm GMT / 4pm CET  Register for the free webcast followed by a live Q & A session  Sponsored by:
RESEARCH HIGHLIGHTS Top Gastric cancer: A master KLASS in laparoscopic gastrectomy Published online: 11 February 2014 p119 | doi:10.1038/nrclinonc.2014.18 PDF Breast cancer: CALOR favours adjuvant therapy for ILRR of breast cancer Published online: 04 February 2014 p120 | doi:10.1038/nrclinonc.2014.13 PDF Lung cancer: Whack a gli hedgehog Published online: 04 February 2014 p121 | doi:10.1038/nrclinonc.2014.15 PDF Radiotherapy: DNA repair—a marker of late toxicity Published online: 28 January 2014 p121 | doi:10.1038/nrclinonc.2014.7 PDF Radiotherapy: Avoiding lymphedema Published online: 28 January 2014 p121 | doi:10.1038/nrclinonc.2014.8 PDF Breast cancer: Progress from NOAH study comes in twos Published online: 04 February 2014 p122 | doi:10.1038/nrclinonc.2014.12 PDF Kidney cancer: Sunitinib has similar efficacy irrespective of age in mRCC Published online: 04 February 2014 p122 | doi:10.1038/nrclinonc.2014.14 PDF Medical oncology: Cardiovascular events linked to levels of cortisol production Published online: 18 February 2014 p123 | doi:10.1038/nrclinonc.2014.19 PDF New technology: Improved nanoparticle delivery and elimination—it's in the DNA Published online: 18 February 2014 p124 | doi:10.1038/nrclinonc.2014.20 PDF Screening: High-throughput screen identifies a roadmap for combination drug trials Published online: 11 February 2014 p124 | doi:10.1038/nrclinonc.2014.21 PDF CNS cancer: New options for glioblastoma Published online: 18 February 2014 p124 | doi:10.1038/nrclinonc.2014.27 PDF IN BRIEF Genetics: Early onset kidney cancer should trigger genetic analysis | Haematological cancer: A new treatment option for relapsed and refractory MM | Pancreatic cancer: Optimal timing for post-surgery chemotherapy | Breast cancer: Overcoming resistance with dual HER2 blockade | Breast cancer: Enzalutamide—a new treatment for ER-positive disease | Pancreatic cancer: Frondoside A enhances the effects of gemcitabine PDF Clinical Oncology JOBS of the week Assistant Professorship in Medical Physics in Radiation Oncology University of Zurich - Faculty of Medicine Postdoctoral Fellow In Biomarker Discovery In Prostate Cancer University of California - San Francisco Postdoctoral Fellow - Cancer Biology Dana-Farber Cancer Institute / Harvard Medical School Postdoc Cancer Biology for Drug Discovery Italian Institute of Technology (ITT) Targeting mitotic-exit phosphatases for cancer therapy KU Leuven More Science jobs from Clinical Oncology EVENT Powering the Cancer Machine 06.07.14 Glasgow, UK More science events from
NEWS AND VIEWS		Top
Genetics: CALR mutations and a new diagnostic algorithm for MPN Ayalew Tefferi & Animesh Pardanani Published online: 11 February 2014 p125 | doi:10.1038/nrclinonc.2014.16 Between 2005 and 2007, mutations in JAK2 and MPL were described in most patients with myeloproliferative neoplasms (MPN). These seminal discoveries have forever changed our diagnostic approach to MPN. In December 2013, mutations in CALR were reported in MPN wild-type for JAK2 and MPL. These mutations provide additional diagnostic and prognostic tools in MPN. Full Text | PDF
Prevention: Targeted therapy—anastrozole prevents breast cancer Powel Brown Published online: 18 February 2014 p127 | doi:10.1038/nrclinonc.2014.17 The recent IBIS-II clinical trial results demonstrate anastrozole reduces breast cancer incidence by 53% in postmenopausal women. While this is a major advance in prevention research, its impact on clinical practice will ultimately depend upon subject perception of risk, adverse effects and benefits of anastrozole versus other available cancer preventive therapies. Full Text | PDF
REVIEWS		Top
Molecular analysis of circulating tumour cells—biology and biomarkers Matthew G. Krebs, Robert L. Metcalf, Louise Carter, Ged Brady, Fiona H. Blackhall & Caroline Dive Published online: 21 January 2014 p129 | doi:10.1038/nrclinonc.2013.253 Advances in single-cell molecular analysis are enhancing our ability to explore the mechanisms of metastasis. In this Review, the authors describe how circulating tumour cells (CTCs), captured from a minimally invasive blood test—and readily amenable to serial sampling—have the potential to inform intratumour heterogeneity and tumour evolution. Abstract | Full Text | PDF
Clinical relevance of circulating cell-free microRNAs in cancer Heidi Schwarzenbach, Naohiro Nishida, George A. Calin & Klaus Pantel Published online: 04 February 2014 p145 | doi:10.1038/nrclinonc.2014.5 The discovery of miRNAs in body fluids has opened up the possibility of using them as non-invasive biomarkers in cancer detection and as predictors of therapy response in cancer treatment. This Review article considers the latest developments in the use of circulating microRNAs as prognostic and predictive biomarkers and discusses their utility in personalized medicine. Abstract | Full Text | PDF | Supplementary information
Bilateral breast cancers Steven A. Narod Published online: 04 February 2014 p157 | doi:10.1038/nrclinonc.2014.3 Bilateral mastectomy is used to treat an increased percentage of women with unilateral breast cancer in order to prevent a second primary cancer in the unaffected breast. Although this surgical approach has been proposed to benefit women at high risk of contralateral cancer, the decision to remove the contralateral breast is controversial and requires a careful evaluation on an individual basis. This Review discusses the risk factors for contralateral breast cancer, and the evidence that bilateral mastectomy might in fact reduce breast-cancer associated mortality. Abstract | Full Text | PDF
Cancer Systems Biology: a peek into the future of patient care? Henrica M. J. Werner, Gordon B. Mills & Prahlad T. Ram Published online: 04 February 2014 p167 | doi:10.1038/nrclinonc.2014.6 Systems biology approaches are beginning to provide information that will enable a more complete view of how the genomic and epigenetic aberrations in cancer cells can alter the homeostasis of signalling networks within the tumour and surrounding microenvironment, both at the organ and organism level. This Review describes the potential of these systems-based approaches and how they are becoming vital for the development and implementation of effective drug discovery and personalized cancer therapy. Abstract | Full Text | PDF
Advertisement
FREE poster on: Helicobacter pylori Helicobacter pylori is an important human pathogen that is transmitted between humans, especially in areas of poor sanitation. H. pylori infection causes gastric mucosal inflammation that can lead to stomach ulcers and gastric cancer. This poster shows the risk factors for these clinical outcomes, their pathological characteristics and current diagnostic and treatment approaches.  Available to download, FREE This poster was produced with support from Aptalis.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2012. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.